Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides

MGF

Growth Hormone
Phase 1 Research
25%
Low-Moderate Risk
2/5

Warnings

Extremely short half-life
May promote tumor growth
Research compound only
No human clinical trials

Contraindications

Active CancerPregnancyBreastfeeding

Drug Interactions

InsulinIGF-1Growth Hormone

Possible Side Effects

Injection Site PainLocalized SwellingHypoglycemia

Legal & Regulatory

FDA Status Research Only
WADA Status Prohibited in Sport
Prescription Not Required

Pregnancy

Category X - Contraindicated